Cargando…

Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real‐world database

The outcomes and best treatment strategies for germline BRCA1/2 mutation (gBRCAm) carriers with metastatic breast cancer (MBC) remain uncertain. We compared the overall survival and the first line progression free survival (PFS1) of patients with a gBRCAm identified at initiation of first‐line treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mailliez, Audrey, D'Hondt, Veronique, Lusque, Amelie, Caron, Olivier, Cabel, Luc, Goncalves, Anthony, Debled, Marc, Gladieff, Laurence, Ferrero, Jean‐Marc, Petit, Thierry, Mouret‐Reynier, Marie Ange, Eymard, Jean‐Christophe, Levy, Christelle, Uwer, Lionel, Leheurteur, Marianne, Desmoulins, Isabelle, Bachelot, Thomas, Frenel, Jean‐Sebastien, de la Motte Rouge, Thibault, Simon, Gaëtane, Jacot, William, Delaloge, Suzette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Cancer Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092337/ https://www.ncbi.nlm.nih.gov/pubmed/36161271 http://dx.doi.org/10.1002/ijc.34304

Ejemplares similares

Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study
por: Vasseur, Antoine, et al.
Publicado: (2022)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database
por: Carausu, Marcela, et al.
Publicado: (2022)

Real-world evidence of the management and prognosis of young women (⩽40 years) with de novo metastatic breast cancer
por: Mallet, Amélie, et al.
Publicado: (2022)

Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
por: François-Martin, Hélène, et al.
Publicado: (2023)

Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
por: Moinard-Butot, Fabien, et al.
Publicado: (2022)

Impact of body mass index on overall survival in patients with metastatic breast cancer
por: Saleh, Khalil, et al.
Publicado: (2020)

Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
por: Darlix, Amélie, et al.
Publicado: (2019)

Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes
por: Carausu, Marcela, et al.
Publicado: (2022)

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort
por: Frank, Sophie, et al.
Publicado: (2020)

Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program
por: Le Du, Fanny, et al.
Publicado: (2023)

CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
por: Gougis, P., et al.
Publicado: (2019)

Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort
por: Grinda, T., et al.
Publicado: (2021)

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
por: Cabel, Luc, et al.
Publicado: (2021)

Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
por: Sirieix, Junien, et al.
Publicado: (2020)

Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer
por: Bortolini Silveira, Amanda, et al.
Publicado: (2021)

Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
por: Lerebours, Florence, et al.
Publicado: (2020)

Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database
por: Carausu, M., et al.
Publicado: (2021)

Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
por: Bertho, Marion, et al.
Publicado: (2021)

Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1
por: Berger, Frédérique, et al.
Publicado: (2022)

Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study
por: Alhenc-Gelas, Marion, et al.
Publicado: (2021)

Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database
por: Annonay, Mylène, et al.
Publicado: (2021)

Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review
por: Classe, Jean-Marc, et al.
Publicado: (2021)

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
por: Coudert, Bruno, et al.
Publicado: (2020)

Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system
por: Feunteun, Jean, et al.
Publicado: (2022)

Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME)
por: Dano, D., et al.
Publicado: (2021)

Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer
por: Carbonnier, Vincent, et al.
Publicado: (2023)

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
por: Liang, Xu, et al.
Publicado: (2018)

TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer
por: Gay-Bellile, Mathilde, et al.
Publicado: (2017)

Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study
por: Bidard, François-Clément, et al.
Publicado: (2012)

Insights adjusting for non-adherence in randomized clinical trials: a reanalysis of an adjuvant trial of tamoxifen duration in early breast cancer
por: Giudici, Fabiola, et al.
Publicado: (2023)

Effectiveness of a Global Multidisciplinary Supportive and Educational Intervention in Thermal Resort on Anthropometric and Biological Parameters, and the Disease-Free Survival after Breast Cancer Treatment Completion (PACThe)
por: Vasson, Marie-Paule, et al.
Publicado: (2020)

VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study
por: Gal, Jocelyn, et al.
Publicado: (2020)

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases
por: Braccini, Antoine-Laurent, et al.
Publicado: (2013)

Dépistage et diagnostic du cancer du sein à la fin de période de confinement COVID-19, aspects pratiques et hiérarchisation des priorités()
por: Ceugnart, Luc, et al.
Publicado: (2020)

Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2–14)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Oral mucositis induced by anticancer treatments: physiopathology and treatments
por: Lionel, D'Hondt, et al.
Publicado: (2006)

BRCA1/2 carriers: their childbearing plans and theoretical intentions about having preimplantation genetic diagnosis and prenatal diagnosis
por: Julian-Reynier, Claire, et al.
Publicado: (2012)

Onco-gynecologic surgery in the COVID-19 era: Risks and precautions—A position paper from FRANCOGYN, SCGP, SFCO, and SFOG
por: Lavoué, Vincent, et al.
Publicado: (2020)

Comparison between primary Sjögren’s disease patients with high or low level of dryness
por: Kachaner, Alexandra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_06nkdqp87fb0vh2s3d0qtl7g4m